Lilly’s Neurodegeneration pipeline is one of the deepest in the industry and is shaped by the discoveries we’ve made over nearly three decades of research and development. Our current program is focused predominantly on developing disease-modifying therapies that slow or halt the progression of Alzheimer’s disease. We’re also studying ways to treat the symptoms of other forms of dementia. Lilly is honored to be a part of other leading, independent collaborations in the broader Alzheimer’s disease scientific community.
Lilly and Alzheimer’s
Listen to episode 3 of Lilly’s podcast, The Elixir Factor, to hear Academy Award–nominated filmmaker and health care advocate, James Keach, discuss the making of the documentary Turning Point, which granted him access into “the cave” as the Lilly team learned the fate of the Alzheimer’s Expedition 3 study.
To learn more about the Alzheimer’s and the research studies Lilly is conducting, please visit Lilly TrialGuide.